Edgewise Therapeutics will showcase the new cardiac program at the Virtual Investor Event on Tuesday, January 3, 2023

Webcast Event to Present Preclinical Data of its Leading Hypertrophic Cardiomyopathy (HCM) Candidate and Commentary from a Renowned Cardiologist –

Management will provide the company’s outlook for 2023 at 41st JP Morgan Healthcare Annual Conference January 10, 2023 –

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable small molecule targeted therapies for the treatment of devastating muscle disorders, today announced plans to host a call for Virtual Investors Tuesday, January 1, 3, 2023, at 8:30am ET. The webcast event will feature a presentation of preclinical results for its lead cardiac program candidate, EDG-7500, initially aimed at patients with HCM, and will include commentary from a leading cardiology expert.

“EDG-7500 represents Edgewise’s new investigational candidate emerging from our highly productive discovery platform aimed at identifying cardiovascular therapies with differentiated mechanisms of action,” said Kevin Koch, Ph.D., President and Chief Executive Officer, Edgewise Therapeutics. “We believe our preclinical data set on EDG-7500 suggests it may address important unmet medical needs in the treatment of HCM. We are planning to file an IND application in the second half of 2023.”

A live webcast of the event will be available on the Events & Presentations page of the Edgewise website and a replay will be accessible for a limited time after the event. An accompanying slide presentation will also be available. To register for the live webcast and replay, visit the Edgewise Events page.

Additionally, Edgewise plans to share this data and the company’s outlook for 2023 to 41st JP Morgan Healthcare Annual Conference on January 10, 2023.

Presentation of Edgewise Therapeutics at the JP Morgan Annual Healthcare Conference

Edgewise Therapeutics President and Chief Executive Officer Kevin Koch, Ph.D., will present at the 41st JP Morgan Healthcare Annual Conference on January 10, 2023, at 12:45 PM ET / 9:45 AM PT. The presentation will be broadcast live on the web; a link for the webcast is available on Edgewise’s events page and will be accessible for replay after the presentation. Users are advised to connect to the webcast several minutes before it starts to ensure timely connection.

About Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe and rare neuromuscular and cardiac disorders for which there is a significant unmet medical need. Guided by its holistic approach to drug discovery to target muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary muscle-centric drug discovery platform. Edgewise’s platform uses high-throughput, custom-translatable systems that measure integrated muscle function in whole organ extracts to identify precision small-molecule drugs that regulate key proteins in muscle tissue. The company’s lead candidate, EDG-5506, an orally administered small-molecule myosin modulator designed to protect fast skeletal muscle fibers susceptible to injury in dystrophinopathies, is advancing in multiple clinical trials in individuals with Duchenne muscular dystrophy or Becker muscular dystrophy. To find out more, go to: www.edgewisetx.com or follow us on LinkedIn, Chirping and Facebook.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential and expectations relating to Edgewise’s drug discovery platform, product candidates and programs, including the cardiac program; Statements about the timing of filing an IND for Edgewise’s cardiac program; and statements from Edgewise’s chairman and chief executive officer and Edgewise’s director of development. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained herein are based on Edgewise’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: Risks associated with the process of discovering, developing, and commercializing safe and effective medicines for use as human and operate as an early stage company, including the potential for Edgewise’s product candidates to cause serious adverse events; Edgewise’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for, and commercialize any of its product candidates; the timing, progress and results of preclinical studies and clinical trials for Edgewise’s product candidates; Edgewise’s ability to raise any additional funding it will need to continue to pursue its product and commercial development plans; adverse impacts of the COVID-19 pandemic on Edgewise’s operations, including preclinical and clinical studies; the timing, scope and likelihood of filings and regulatory approvals; the potential for clinical trial results to differ from preclinical, interim, preliminary, topline, or anticipated results; Edgewise’s ability to develop a proprietary drug discovery platform to create a pipeline of product candidates; Edgewise’s manufacturing, commercialization and marketing capabilities and strategy; the size of the market opportunity for Edgewise’s product candidates; the loss of key management or scientific personnel; competition in the industry in which Edgewise operates; Edgewise’s reliance on third parties; Edgewise’s ability to obtain and maintain intellectual property protection for its product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks can be found in the section entitled “Risk Factors” in documents Edgewise files from time to time with the United States Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Edgewise undertakes no obligation to update any forward-looking statements or to update any reason why actual results could differ from those projected in the forward-looking statements, except as required by law..

Add a Comment

Your email address will not be published. Required fields are marked *